Influenza is a frequently occurring disease throughout the world. It is seasonal, spreads quickly and has a high incidence. The control of influenza virus epidemics has been one of the major health challenges for many decades. The early treatments, amantadine and rimantadine (Stephen et al., 1977; Wilson et al., 1980; Heider et al., 1981) , and to a limited extent ribavirin (Eriksson et al., 1977; Wray et al., 1985 Wray et al., , 1986 Wyde et al., 1986; Shigeta et al., 1988) , suffer from a narrow activity spectrum, in that they are active against influenza virus type A, but not type B. The use of newer neuraminidase inhibitors against influenza types A and B is now recommended (Sidwell et al., 1998; Burger et al., 2000) , but they are expensive and it remains to be seen how effective they will be in the long term.
Recently, considerable attention has been paid to the antiviral activity of heteropoly compounds (Bussereau et al., 1988; Moskovitz et al., 1988; George et al., 1990; Inouye et al., 1993; Yamase et al., 1996; Jeffrey et al., 1998) , and many researchers have reported their broad-spectrum antiviral activity (Tomita et al., 1989; Hill et al., 1990; Inouye et al., 1991 Inouye et al., , 1992 Weeks et al., 1992; Ni et al., 1996) . Some compounds exhibit inhibitory activity against a number of viruses, such as HIV, herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2) human cytomegalovirus (HCMV) and influenza virus (Fukuma et al., 1991; Take et al., 1991; Ikeda et al., 1994; Kim et al., 1994; Morj et al., 1995; Huffman et al., 1997) . Ikeda et al. have studied the antiviral activity of [PTi 2 W 10 O 40 ]•6H 2 O) in ddY mice. Results indicated that it was a good inhibitor of HSV-1 and HSV-2, preventing the death of mice infected with these viruses (Ikeda et al., , 1994 Ni et al., 1994) . However, heteropolymetalates are unstable at physiological pH -a relatively low pH being required to keep them stable -so their effects are short-lived. The heteropoly acids were reduced to heteropoly blues by electrolysis to resolve this problem (Cansan-Pastor et al., 1991 . Heteropoly blues are mixed-valence complexes (Sanchez et al., 1982; Pope, 1983) , usually containing W(VI) and W(V), Mo(VI) and Mo(V), V(V) and V(IV). In contrast to their parent heteropoly acids, the heat stability and the acid and base stability of heteropoly blues were significantly improved (Liu et al., 1998 (Liu et al., , 1999 .
We have demonstrated that the heteropoly blue HPB-2 has marked efficacy in cells against influenza virus. In the present study, we investigated the toxicity and antiviral activity against influenza virus of HPB-2 in Kunming mice. The results indicated that HPB-2 effectively reduced the degree of consolidation in lungs and prevented death of 
Materials and Methods

Animals
Toxicity and Ames tests of HPB-2
Mice were divided into groups at random. HPB-2 was given either orally or intraperitoneally, as a single dose or twice daily, for 4 days to assess acute and chronic toxicity. Control mice were injected i.p. or p.o. with physiological saline. Mice were observed for adverse events, and death was recorded after 10 days. Autopsy was also carried out, and the 50% lethal doses (LD 50 ) of acute and chronic toxicity were calculated. The Ames tests were by the method of Ames and McCann.
Therapeutic effect of HPB-2 on the mice infected with influenza virus FM1
From the results of accumulated toxicity experiments by i.p. and p.o. administration, an appropriate non-toxic dose of HPB-2 was chosen. The complex was diluted with physiological saline and administered p.o. at doses of 200, 100, 50 and 20 mg/kg, respectively, and by i.p. at doses of 20, 10, 2 and 1 mg/kg, respectively. These were then tested in parallel with ribavirin at a dose of 200 mg/kg.
Mice were anaesthetized by diethylether and then dripnose-infected with 4 LD 50 (10 -4 dilution) of FM1 at 0.04 ml/mouse. They were then administered twice daily with HPB-2, or once daily with ribavirin, for 4 days, tested in parallel with a no-treatment group (injected i.p. or p.o. with physiological saline twice daily), a compound group (not infected with virus and administed i.p. or p.o. with the largest dose of compound twice daily) and a normal group. The mice were observed daily for 14 days. Mortality and body weight of mice in each group were recorded. The 50% effective dose (ED 50 ) was calculated by Reed-Muench method and the TI was obtained.
Activity of HPB-2 against pneumonia in influenza virus FM1-infected mice
Materials and methods were similar to the procedure above, except that the end-point measured was pneumonia. Five days after infection with the virus, the mice were killed by cervical dislocation, weighed and the lungs were removed. The lungs were washed in physiological saline, dried on stet and weighed. The pathological changes of the lungs were observed and described as '+', '++', '+++' or/and '++++', and the consolidation index of lungs was calculated (consolidation index of the lungs = the weigh of the mouse's lung/the weight of the mouse's body).
Results
Toxicity of HPB-2
Groups of 10 mice were used in the toxicity studies. Different doses of the test HPB-2 were administered by the i.p. and p.o. route. The mice were observed daily for 10 days, and deaths were recorded. The results of acute toxicity and accumulated toxicity of HPB-2 in the mice are shown in Table 1 . Regardless of the route of administration (i.p. or p.o.), mice that died were dead within 24 h. All mice that died were examined microscopically for changes in the large organs of the abdominal and thoracic cavities. The 50% lethal dose of i.p. administration was far less than that of p.o. administration, which indicated that the compound was more toxic when given by this route. Survivors increased in weight slowly, as compared to the normal group. The difference was not significant (P>0.05). The results of an Ames test indicated that the compounds are not mutagenic.
Activity of HPB-2 against influenza virus in mice
The medical effect of a compound is usually related to its toxicity. The assessment index is expressed by the ratio of 50 lethal dose (LD 50 ) to 50 effective dose (ED 50 ) (Ikeda et al., 1994) . This ratio is the therapeutic index, TI (TI=LD 50 /ED 50 ). The results of the present experiment are shown in 
Survival rates
The results (Figures 1 and 2 ) indicated that the survival rates of mice infected with influenza virus were significantly improved by treatment at doses of 200, 100 and 50 mg/kg of HPB-2 (p.o.), and 20, 10 and 2 mg/kg of HPB-2 (i.p.).
In the present study, mice without any treatment died within 4-8 days, the survival rates being 0-10%. However, after being treated with heteropoly compound, the survival rates increased markedly. At p.o. doses of 200 and 100 mg/kg, the survival rates were 100 and 90%, respectively. The survival rates decreased with dose.
When the mice were administered p.o. with ribavirin at a dose of 200 mg/kg, the survival rate was 70%, a lesser effect to that of HPB-2 at 200 or 100 mg/kg p.o. doses, and comparable to that of the 50 mg/kg p.o. dose. The survival rate was 90% for mice administered i.p. with HPB-2 at doses of 20 and 10 mg/kg, again higher than the survival rate of 70% observed in those administered i.p. with ribavirin at a dose of 200 mg/kg. When the doses were reduced to 2 and 1 mg/kg, survival rates decreased. Survival rates were clearly dose-dependent (Figures 1 and 2 ).
The effect of HPB-2 on pneumonia in mice infected with influenza virus FM1
Mice were administered with HPB-2 i.p. and p.o. Pathological changes and average lung consolidation index were used as the assessment indices of the treatment effect [lung index = (lung weight of a mouse/body weight of a mouse)×100%; lung index inhibition rate = (average lung index of no treatment group -average lung index of the treatment group)/average lung index of the control group]. Results are shown in Table 3 . The lung index inhibition rates were 51, 49 and 36% at the p.o. administration doses of 200, 100 and 50 mg/kg, respectively. The average lung index in the treatment group was statistically different to that of the no-treatment group. The lung index inhibition rate was 27% at p.o. doses of 20 mg/kg, which was not statistically different to that of the no-treatment group. This indicated that HPB-2 had a marked treatment effect in the range of 50-200 mg/kg. When doses were less than 20 mg/kg, there was no treatment effect.
When the i.p. doses were 20, 10 and 2 mg/kg, the lung index inhibition rates were 51, 49 and 41%, respectively. The lung index inhibition rates of the treatment groups were statistically different to those of the no-treatment groups, which indicated that a marked curative effect of i.p. HPB-2 doses is achieved in the range of 2-20 mg/kg.
Another index to assess the curative effect is mouse lung pathology. Without treatment, lungs exhibited severe pathological changes. Lungs were largely necrotic with dark purple spots, while mice treated with HPB-2, especially those administered with large doses, had no lung pathological changes. The lung pathological changes in the no-treatment group were all scored above '+++' and mice died after 5 days. When the p.o. dose was 200 mg/kg, only one mouse lung showed pathological changes with a score of '+'. When the p.o. dose was 100 mg/kg, one mouse lung was scored '+', and a second was scored '+++'. The degree of pathological change was obviously reduced. Similar results were observed in the i.p. group and the curative effect was greater than that in the p.o. group.
Comparison between curative effects of HPB-2 and ribavirin
From the degree of lung pathological changes in treated groups, it can be seen that the curative effects in groups administered HPB-2 p.o. at doses of 200 and 100 mg/kg were greater than those of the group given ribavirin at a dose of 200 mg/kg. When doses of 50 mg/kg were administered, the curative effect was comparable to that of the group given ribavirin.
The treatment effects in the three groups administered HPB-2 i.p. at doses of 20, 10 and 2 mg/kg were better than those with ribavirin at a dose of 200 mg/kg. Given HPB-2 either i.p. or p.o., the weight of mice treated at high doses were not different from those of the normal group, again suggesting that the compound was effective. In this experiment, the high doses were safe and effective, but at low doses of 20 mg/kg (p.o.) and 1 mg/kg (i.p.), there were significant differences in weight between the treated groups and the normal group due to the disease, HPB-2 had no effect on inhibiting influenza virus at this dose. In contrast to the normal group, the mice treated with ribavirin lost weight significantly. This suggested that, although ribavirin was prohibitive, it also had some toxic side-effects. These results also showed that HPB-2 is an excellent antiviral compound with low toxicity and greater efficacy than ribavirin.
Discussion
Effects of administration routes on treatment effects
The 50% effective doses (ED 50 ) of HPB-2 when given orally was 26.4 mg/kg, and the therapeutic index (TI) was 95. The ED 50 when given i.p. was 1.45 mg/kg and the TI was 245. From the TI, it can be seen that i.p. administration showed better curative effects than p.o. administration.
The efficacy in the i.p. group was greater than that in the p.o. group. For example, at the same dose of 20 mg/kg, the survival rates were 90% following i.p. administration and 60% following p.o. administration. HPB-2 has greater efficacy when administrated by the i.p. route. This also indicated that the curative effect of i.p. administration is superior.
The experimental results indicated that HPB-2 was effective in protecting mice infected with influenza virus FM1. It improved the survival of infected mice and reduced the incidence of pneumonia. The curative effect was dependent on the dose of HPB-2.
Effects of HPB-2 on the weight of mice in treament group
Mice treated with HPB-2, either by the i.p. or by the p.o. route, had no significant difference in weight compared with normal mice. The relationships between the doses of HPB-2 and the weight increase of mice are shown in Figures 3 and 4 .
On the basis of the effects of administration route and dose of HPB-2 on mouse weight, the selected doses in this experiment had no toxic effects. When the dose of ribavirin in the comparative group was 200 mg/kg, whether administered i.p. or p.o., the mice grew more slowly than those treated with HPB-2. This indicates that ribavirin has some toxic effects in these dose ranges.
The above results suggest that the use of HPB-2 would be preferable to that of ribavirin. Although ribavirin has inhibitory activity to influenza virus in mice and in cells, and some efficacy in the clinic, it is still rarely used to treat influenza due to high toxicity, which may cause anaemia, hepatocirrhosis (liver damage), nausea, vomiting and terotome. The heteropoly blue HPB-2 with low toxicity and high antiviral activity is potentially a good medicine.
